Cover Image
市場調查報告書

MediPoint:人工骨替代材料(BGS)- 現在/未來的主要企業

MediPoint: Bone Grafts and Substitutes - Current and Future Players

出版商 GlobalData 商品編碼 296806
出版日期 內容資訊 英文 122 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint:人工骨替代材料(BGS)- 現在/未來的主要企業 MediPoint: Bone Grafts and Substitutes - Current and Future Players
出版日期: 2014年01月31日 內容資訊: 英文 122 Pages
簡介

骨移植公認是以自體骨當作代表性移植材料,不過市場上可利用的人工骨骼替代物相當廣泛,尤其是美國和歐洲市場有增加採用人工骨替代材料(BGS)的趨勢。相對於已開發國家,在亞太地區和南非,自體骨是最常見的選項。

本報告提供全球BGS市場相關調查分析,聚焦包含新加入廠商的競爭情形,再加上主要企業相關最新資訊詳細分析,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 臨床結果

  • 概要
  • 自體骨
  • 異體骨
  • 人工骨替代材料(BGS)

第4章 競爭評估

  • 概要
  • 上市產品

第5章 開發中產品

  • 概要
  • Advanced Biologics:OsteoMEM
  • Aursos:Synthetic Bone Substitute
  • BioSET:AMPLEX
  • CeraPedics:i-FACTOR
  • NuVasive:AttraX
  • Osiris Therapeutics:OvationOS
  • Wright Medical:Augment Bone Graft

第6章 值得注意的臨床試驗

  • Medtronic:INFUSE Bone Graft
  • Wright Medical:Augment Bone Graft
  • Orthofix:Trinity Evolution
  • AlloSource:AlloStem
  • NuVasive:AttraX
  • CeraPedics:i-FACTOR
  • BioSET:AMPLEX

第7章 現在/未來的主要企業

  • 企業策略趨勢
  • 企業簡介
    • Alphatec Spine
    • AlloSource
    • Bacterin
    • Biomet
    • DePuy Synthes
    • Exactech
    • Globus Medical
    • Integra LifeSciences
    • Medtronic
    • NuVasive
    • Olympus Biotech
    • Orthofix
    • RTI Surgical
    • Stryker
    • Wright Medical
    • Zimmer Holdings
  • 其他的企業

第8章 附錄

圖表

目錄
Product Code: GDME1020FPR

Although autograft is still perceived as the gold-standard material in bone grafting, the wide array of alternatives available in the market has resulted in a gradual shift towards increased adoption of bone grafts and substitutes (BGS), especially in the US and European markets. In contrast to the general picture in developed countries, autograft bone still represents the most popular option during bone grafting in the Asia-Pacific (APAC) region and South America.

The report identifies and analyzes the key companies shaping and driving the global BGS market. The report provides insight into the competitive BGS landscape, including new companies entering the market and pipeline products in development. This report is built using data and information sourced from proprietary databases, secondary sources and primary research interviews and survey with leading cardiologists, with in-house analysis conducted by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for BGS.
  • Competitor assessment including device approval analysis.
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of the device sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists using BGS devices in clinical practice.

Reasons to buy

  • Gain a high level view of the trends shaping and driving the BGS market for coronary applications and peripheral applications in the lower extremity.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Clinical Outcomes

  • 3.1. Overview
  • 3.2. Autograft Bone
  • 3.3. Allograft Bone
  • 3.4. Bone Graft Substitutes
    • 3.4.1. BMPs/Growth Factors
    • 3.4.2. DBMs
    • 3.4.3. Synthetic Bone Substitutes
    • 3.4.4. Cell-Based Matrices

4. Competitive Assessment

  • 4.1. Overview
  • 4.2. Marketed Products
    • 4.2.1. Advanced Biologics
    • 4.2.2. AlloSource
    • 4.2.3. Bacterin
    • 4.2.4. Baxter
    • 4.2.5. Biomet
    • 4.2.6. DePuy Synthes
    • 4.2.7. Exactech
    • 4.2.8. Integra LifeSciences
    • 4.2.9. Medtronic
    • 4.2.10. Musculoskeletal Transplant Foundation (MTF)
    • 4.2.11. NuVasive
    • 4.2.12. Olympus Biotech
    • 4.2.13. Orthofix
    • 4.2.14. RTI Surgical
    • 4.2.15. Stryker
    • 4.2.16. Wright Medical
    • 4.2.17. Zimmer

5. Pipeline Products

  • 5.1. Overview
  • 5.2. Advanced Biologics' OsteoMEM
  • 5.3. Aursos' Synthetic Bone Substitute
  • 5.4. BioSET's AMPLEX
  • 5.5. CeraPedics' i-FACTOR
  • 5.6. NuVasive's AttraX
  • 5.7. Osiris Therapeutics' OvationOS
  • 5.8. Wright Medical' Augment Bone Graft

6. Clinical Trials to Watch

  • 6.1. Yale's Review of Medtronic's INFUSE Bone Graft
  • 6.2. Wright Medical's Augment Bone Graft
  • 6.3. Orthofix's Trinity Evolution
  • 6.4. AlloSource's AlloStem
  • 6.5. NuVasive's AttraX
  • 6.6. CeraPedics' i-FACTOR
  • 6.7. BioSET's AMPLEX

7. Current and Future Players

  • 7.1. Trends in Corporate Strategy
  • 7.2. Company Profiles
    • 7.2.1. Alphatec Spine
    • 7.2.2. AlloSource
    • 7.2.3. Bacterin
    • 7.2.4. Biomet
    • 7.2.5. DePuy Synthes
    • 7.2.6. Exactech
    • 7.2.7. Globus Medical
    • 7.2.8. Integra LifeSciences
    • 7.2.9. Medtronic
    • 7.2.10. NuVasive
    • 7.2.11. Olympus Biotech
    • 7.2.12. Orthofix
    • 7.2.13. RTI Surgical
    • 7.2.14. Stryker
    • 7.2.15. Wright Medical
    • 7.2.16. Zimmer Holdings
  • 7.3. Other Players

8. Appendix

  • 8.1. Abbreviations
  • 8.2. Bibliography
  • 8.3. Report Methodology
    • 8.3.1. Overview
    • 8.3.2. Coverage
    • 8.3.3. Secondary Research
    • 8.3.4. Forecasting Methodology
    • 8.3.5. Primary Research. Key Opinion Leader Interviews
    • 8.3.6. Expert Panel Validation
  • 8.4. Physicians and Specialists Included in this Study
  • 8.5. About the Authors
    • 8.5.1. Analysts
    • 8.5.2. Bonnie Bain, Ph.D., Global Head of Healthcare
  • 8.6. About MediPoint
  • 8.7. About GlobalData
  • 8.8. Disclaimer

List of Tables

  • Table 1: Definition of Bone Growth Mechanisms
  • Table 2: Advantages and Disadvantages of Autografts
  • Table 3: Advantages and Disadvantages of Allografts
  • Table 4: Differences Between INFUSE Bone Graft and OP-1 Products
  • Table 5: Advantages and Disadvantages of BMPs
  • Table 6: Advantages and Disadvantages of DBMs
  • Table 7: Major Types of Synthetic Bone Substitutes
  • Table 8: Advantages and Disadvantages of Synthetic Bone Substitutes
  • Table 9: Advantages and Disadvantages of Cell-Based Matrices
  • Table 10: Advanced Biologics' BGS Products
  • Table 11: SWOT Analysis - Advanced Biologics' BGS Portfolio
  • Table 12: AlloSource's BGS Products
  • Table 13: SWOT Analysis - AlloSource's BGS Portfolio
  • Table 14: Bacterin's BGS Products
  • Table 15: SWOT Analysis - Bacterin's BGS Portfolio
  • Table 16: Baxter's BGS Products
  • Table 17: SWOT Analysis - Baxter's BGS Portfolio
  • Table 18: Biomet's BGS Products
  • Table 19: SWOT Analysis - Biomet's BGS Portfolio
  • Table 20: DePuy Synthes' BGS Products
  • Table 21: SWOT Analysis - DePuy Synthes' BGS Portfolio
  • Table 22: Exactech's BGS Products
  • Table 23: SWOT Analysis - Exactech's BGS Portfolio
  • Table 24: Integra LifeSciences' BGS Products
  • Table 25: SWOT Analysis - Integra LifeSciences' BGS Portfolio
  • Table 26: Medtronic's BGS Products
  • Table 27: SWOT Analysis - Medtronic's BGS Portfolio
  • Table 28: MTF's BGS Products
  • Table 29: SWOT Analysis - MTF's BGS Portfolio
  • Table 30: NuVasive's BGS Products
  • Table 31: SWOT Analysis - NuVasive's BGS Portfolio
  • Table 32: Olympus Biotech's BGS Products
  • Table 33: SWOT Analysis - Olympus Biotech's BGS Portfolio
  • Table 34: Orthofix's BGS Products
  • Table 35: SWOT Analysis - Orthofix's BGS Portfolio
  • Table 36: RTI Surgical's BGS Products
  • Table 37: SWOT Analysis - RTI Surgical's BGS Portfolio
  • Table 38: Stryker's BGS Products
  • Table 39: SWOT Analysis - Stryker's BGS Portfolio
  • Table 40: Wright Medical's BGS Products
  • Table 41: SWOT Analysis - Wright Medical's BGS Portfolio
  • Table 42: Zimmer's BGS Products
  • Table 43: SWOT Analysis - Zimmer's BGS Portfolio
  • Table 44: Pipeline Products in the Global BGS Market
  • Table 45: Major Clinical Findings of the YODA Project
  • Table 46: Major Clinical Studies of Augment Bone Graft
  • Table 47: Major Clinical Studies of Trinity Evolution
  • Table 48: Major Clinical Study of AlloStem
  • Table 49: Major Clinical Study of AttraX
  • Table 50: Major Clinical Study of i-FACTOR
  • Table 51: Major Clinical Studies of AMPLEX
  • Table 52: Company Profile - Alphatec Spine
  • Table 53: SWOT Analysis - Alphatec Spine
  • Table 54: Company Profile - AlloSource
  • Table 55: SWOT Analysis - AlloSource
  • Table 56: Company Profile - Bacterin
  • Table 57: SWOT Analysis - Bacterin
  • Table 58: Company Profile - Biomet
  • Table 59: SWOT Analysis - Biomet
  • Table 60: Company Profile - DePuy Synthes
  • Table 61: SWOT Analysis - DePuy Synthes
  • Table 62: Company Profile - Exactech
  • Table 63: SWOT Analysis - Exactech
  • Table 64: Company Profile - Globus Medical
  • Table 65: SWOT Analysis - Globus Medical
  • Table 66: Company Profile - Integra LifeSciences
  • Table 67: SWOT Analysis - Integra LifeSciences
  • Table 68: Company Profile - Medtronic
  • Table 69: SWOT Analysis - Medtronic
  • Table 70: Company Profile - NuVasive
  • Table 71: SWOT Analysis - NuVasive
  • Table 72: Company Profile - Olympus Biotech
  • Table 73: SWOT Analysis - Olympus Biotech
  • Table 74: Company Profile - Orthofix
  • Table 75: SWOT Analysis - Orthofix
  • Table 76: Company Profile - RTI Surgical
  • Table 77: SWOT Analysis - RTI Surgical
  • Table 78: Company Profile - Stryker
  • Table 79:SWOT Analysis - Stryker
  • Table 80: Company Profile - Wright Medical
  • Table 81: SWOT Analysis - Wright Medical
  • Table 82: Company Profile - Zimmer Holdings
  • Table 83: SWOT Analysis - Zimmer Holdings
  • Table 84: Other Players in the Global BGS Market

List of Figures

  • Figure 1: An Overview of BGS Used in Orthopedic Surgeries
  • Figure 2: Other Primary Research Participants Breakdown, by Country (n=236)
  • Figure 3: Other Primary Research Participants Breakdown, by Institution (n=236)
Back to Top